Enhertu Benefit in HER2-Low Breast Cancer: 'Practice Changing'
Breast cancer patients with low levels of HER2 expression, previously considered untreatable with HER2-targeted therapies, had improved progression-free survival with trastuzumab deruxtecan (Enhertu).
Medscape Medical News
source https://www.medscape.com/viewarticle/975070?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/975070?src=rss
Comments
Post a Comment